SCHEDULE: State Street Discloses 5.5% Stake in Intellia Therapeutics

State Street Corporation has reported a 5.5% beneficial ownership stake in Intellia Therapeutics Inc. as of December 31, 2025.

Summary

• State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Intellia Therapeutics Inc.
• As of December 31, 2025, State Street Corporation beneficially owned 6,418,836 shares of Intellia Therapeutics' common stock.
• This ownership represents 5.5% of the total class of securities.
• State Street Corporation holds shared voting power over 6,045,757 shares and shared dispositive power over all 6,418,836 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Subsidiaries involved in the beneficial ownership include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a Schedule 13G is a factual report, a significant passive stake by a reputable institutional investor like State Street can be interpreted as a vote of confidence in Intellia Therapeutics, suggesting stability and potential for long-term value.

Positives

• A major institutional investor like State Street Corporation holding a significant stake (5.5%) can signal confidence in Intellia Therapeutics' long-term prospects and stability.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment intent.

Negatives

• NA

Risks

• The filing itself does not detail specific risks related to Intellia Therapeutics' operations or financial health, as it is a beneficial ownership report from an institutional investor.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Intellia Therapeutics' future performance or State Street Corporation's future investment intentions beyond the passive nature of the current holding.

Management Comments

• Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership in biotechnology companies like Intellia Therapeutics, which operates in the innovative gene-editing space, is common. Large asset managers often take significant passive stakes in companies with high growth potential or those included in major indices. This filing indicates State Street's continued or new confidence in the sector and Intellia's position within it.

Comparison to Industry Standards

• A 5.5% stake by a major institutional investor like State Street Corporation is a substantial, but not uncommon, holding for a publicly traded biotechnology company. For instance, Vanguard Group and BlackRock often hold similar or larger passive stakes in companies across various sectors, including biotech firms like CRISPR Therapeutics or Editas Medicine, reflecting broad market index tracking or diversified portfolio strategies.
• The declaration of passive investment intent aligns with typical practices for large asset managers, differentiating their holdings from activist investors who might seek to influence corporate strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder may provide a sense of stability and validation for existing shareholders.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers: No direct impact on customers or suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• State Street Corporation will continue to monitor its investment in Intellia Therapeutics Inc. and will file amendments to this Schedule 13G if its beneficial ownership materially changes (e.g., crosses a 10% threshold or drops below 5%).

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by State Street Corporation, which is generally a positive signal of confidence in Intellia Therapeutics. However, a Schedule 13G primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for investors who believe in the company's long-term prospects, as it suggests institutional validation without providing new catalysts for immediate price movement.

Keywords

Intellia Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, CRISPR, Gene Editing